ABI Fluorescence Detection (RUO)2019-07-18T22:53:47+00:00
PRODUCTS

ABI Fluorescence Detection (RUO)

PRODUCTS

ABI Fluorescence
Detection
(RUO)

Providing high quality, standardized molecular research tools.

We exclusively offer a comprehensive selection of PCR-based assays for ABI fluorescence detection, including targeted FLT3 ITD and TKD mutation assays, B- and T-cell clonality assays (based on EuroClonality/BIOMED-2 Concerted Action BMH4-CT98-3936), and translocation assays.
These RUO Product kits are designed to test DNA extracted from a variety of samples to identify targeted mutations, translocations, and clonal populations in suspect lymphoproliferations. Developed under ISO 13485 design control, our kits are used extensively across the world.

Providing high quality, standardized molecular research tools.

We exclusively offer a comprehensive selection of PCR-based assays for ABI fluorescence detection, including targeted FLT3 ITD and TKD mutation assays, B- and T-cell clonality assays (based on EuroClonality/BIOMED-2 Concerted Action BMH4-CT98-3936), and translocation assays.
These RUO Product kits are designed to test DNA extracted from a variety of samples to identify targeted mutations, translocations, and clonal populations in suspect lymphoproliferations. Developed under ISO 13485 design control, our kits are used extensively across the world.
PATIENT INFORMATION

Why it Matters

Detection, assessment and monitoring of point mutations, internal tandem duplications, and chromosomal aberrations can provide important insights.

PCR-based molecular testing is widely recognized as the gold standard to characterize and monitor chromosomal aberrations often associated with leukemias and lymphomas. Providing comprehensive solutions, Invivoscribe offers an array of assays for B- and T-cell gene clonality/rearrangements, point mutations, internal tandem duplications, and chromosome translocations for the study of hematologic malignancies.
TECHNICAL INFORMATION

How it Works

Our assays can standardize testing between laboratories, streamline workflow, and simplify cross-training.

Leukemias and lymphomas are sometimes challenging to identify by morphology, immunohistochemistry, and flow cytometry. Our PCR-based RUO fluorescence detection assays are globally used to assess B and T-cell clonality point mutations, internal tandem duplications, and chromosomal aberrations.
PATIENT INFORMATION

Why it Matters

Detection, assessment and monitoring of point mutations, internal tandem duplications, and chromosomal aberrations can provide important insights.

PCR-based molecular testing is widely recognized as the gold standard to characterize and monitor chromosomal aberrations often associated with leukemias and lymphomas. Providing comprehensive solutions, Invivoscribe offers an array of assays for B- and T-cell gene clonality/rearrangements, point mutations, internal tandem duplications, and chromosome translocations for the study of hematologic malignancies.
TECHNICAL INFORMATION

How it Works

Our assays can standardize testing between laboratories, streamline workflow, and simplify cross-training.

Leukemias and lymphomas are sometimes challenging to identify by morphology, immunohistochemistry, and flow cytometry. Our PCR-based RUO fluorescence detection assays are globally used to assess B and T-cell clonality point mutations, internal tandem duplications, and chromosomal aberrations.

Clonality

Lymphoid cells are different from the other somatic cells in the body as during development, the antigen receptor genes in lymphoid cells undergo somatic gene rearrangement.

Since leukemia and lymphomas originate from the malignant transformation of individual lymphoid cells, all leukemias and lymphomas generally share one or more cell-specific or ‘clonal’ antigen receptor gene rearrangements. Clonality does not always imply malignancy; all results must be interpreted in the context of all other available indicative characteristics. Our tests detect clonal rearrangements and are useful in the characterization of B- and T-cell malignancies.

Clonality

Lymphoid cells are different from the other somatic cells in the body as during development, the antigen receptor genes in lymphoid cells undergo somatic gene rearrangement.

Since leukemia and lymphomas originate from the malignant transformation of individual lymphoid cells, all leukemias and lymphomas generally share one or more cell-specific or ‘clonal’ antigen receptor gene rearrangements. Clonality does not always imply malignancy; all results must be interpreted in the context of all other available indicative characteristics. Our tests detect clonal rearrangements and are useful in the characterization of B- and T-cell malignancies.

RUO

Invivoscribe offers an array of Research Use Only (RUO) ABI fluorescence detection assays.

These molecular based products are used to test DNA extracted from a variety of samples to study clonal B- and T-cell populations suggestive of malignancies, monitor and evaluate residual disease, and determine lineage of leukemias and lymphomas. Our RUO assays are not for use in diagnostic procedures.

RUO

Invivoscribe offers an array of Research Use Only (RUO) ABI fluorescence detection assays.

These molecular based products are used to test DNA extracted from a variety of samples to study clonal B- and T-cell populations suggestive of malignancies, monitor and evaluate residual disease, and determine lineage of leukemias and lymphomas. Our RUO assays are not for use in diagnostic procedures.

FLT3

Mutations on the FLT3 Gene are the most common in subjects with acute Myeloid Leukemia (AML).

These mutations are characterized by an aggressive phenotype and a high prevalence of relapse, occurring in approximately 30% of subjects.
The FLT3 gene encodes a FMS related tyrosine kinase 3 receptor that is normally expressed in many cell types including hematologic stem cells.
Offering the only internationally standardized FLT3 mutation test, our kits detect both FLT3 ITD and FLT3 TKD mutations.

FLT3 ITD

The most prevalent and significant type of FLT3 mutation is an Internal Tandem Duplication (ITD) in the juxtamembrane domain of the receptor.

FLT3 ITD mutations are a heterogeneous type of mutation in location, size, and number. Research has shown FLT3 ITD mutations associated with higher concentrations of leukemic cells, increased incidence of relapse, and decreased overall survival.
Knowing the FLT3 mutation status can help stratify subjects into groups that will receive different investigational treatments.
The signal ratio has been demonstrated to provide prognostic value in both adult and pediatric AML subjects. High FLT3 ITD signal ratios are likely to have less favorable outcomes.

FLT3 TKD

The second most common mutation type in the FLT3 gene is a Tyrosine Kinase Domain (TKD) point mutation in the codon for an aspartate (D835) or an isoleucine (I836) residue that are located in the activation loop of the FLT3 protein.

FLT3 TKD mutations are caused by nucleic acid substitutions and/or deletions that result in a change in the amino acid sequence in this highly conserved catalytic center. TKD mutations result in constitutive autophosphorylation and activation of FLT3.

FLT3

Mutations on the FLT3 Gene are the most common in subjects with acute Myeloid Leukemia (AML).
These mutations are characterized by an aggressive phenotype and a high prevalence of relapse, occurring in approximately 30% of subjects.
The FLT3 gene encodes a FMS related tyrosine kinase 3 receptor that is normally expressed in many cell types including hematologic stem cells.
Offering the only internationally standardized FLT3 mutation test, our kits detect both FLT3 ITD and FLT3 TKD mutations.

FLT3 ITD

The most prevalent and clinically significant type of FLT3 mutation is an Internal Tandem Duplication (ITD) in the juxtamembrane domain of the receptor.

FLT3 ITD mutations are a heterogeneous type of mutation in location, size, and number. Research has shown FLT3 ITD mutations associated with higher concentrations of leukemic cells, increased incidence of relapse, and decreased overall survival.
Knowing the FLT3 mutation status can help stratify patients into groups that will receive different post-remission treatments.
The signal ratio has been demonstrated to provide prognostic value in both adult and pediatric AML patients. Patients with high FLT3 ITD signal ratios are likely to have less favorable outcomes.

FLT3 TKD

The second most common mutation type in the FLT3 gene is a Tyrosine Kinase Domain (TKD) point mutation in the codon for an aspartate (D835) or an isoleucine (I836) residue that are located in the activation loop of the FLT3 protein.

FLT3 TKD mutations are caused by nucleic acid substitutions and/or deletions that result in a change in the amino acid sequence in this highly conserved catalytic center. TKD mutations result in constitutive autophosphorylation and activation of FLT3.

RUO

The FLT3 Mutation Assays detailed in this section are Research Use Only (RUO) PCR-based gel or capillary detection assays intended for the study of FLT3 activating mutations. They are used to test DNA extracted from a variety of samples to identify internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene. FLT3 RUO (Research Use Only) assays are not for use in diagnostic procedures.

RUO

The FLT3 Mutation Assays detailed in this section are Research Use Only (RUO) PCR-based gel or capillary detection assays intended for the study of FLT3 activating mutations. They are used to test DNA extracted from a variety of samples to identify internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene. FLT3 RUO (Research Use Only) assays are not for use in diagnostic procedures.

Translocations

Detection and assessment of translocations can provide important insights to aid in subject stratification.

Certain translocations have been identified to result in the disruption or mis-regulation of normal gene function and contribute to oncogenesis. Our ABI fluorescence detection assays detect these translocations and provide important insights in the studies of chromosomal aberrations suggestive of malignancies, determine leukemia and lymphoma lineages, and monitor and evaluate disease recurrence.

Translocations

Detection and assessment of translocations can provide important insights to aid in subject stratification.

Certain translocations have been identified to result in the disruption or mis-regulation of normal gene function and contribute to oncogenesis. Our ABI fluorescence detection assays detect these translocations and provide important insights in the studies of chromosomal aberrations suggestive of malignancies, determine leukemia and lymphoma lineages, and monitor and evaluate disease recurrence.

RUO

Invivoscribe offers an array of Research Use Only (RUO) ABI fluorescence detection assays.

These products are used to test DNA extracted from a variety of samples to identify and study translocations involved with malignancies. Intended for Research Use Only, not for use in diagnostic procedures.

RUO

Invivoscribe offers an array of Research Use Only (RUO) ABI fluorescence detection assays.

These products are used to test DNA extracted from a variety of samples to identify and study translocations involved with malignancies. Intended for Research Use Only, not for use in diagnostic procedures.